Chemed reported flat consolidated revenue for Q4 2025, with growth in the VITAS hospice segment offset by a decline in Roto-Rooter performance. While VITAS saw increased admissions and patient census, Roto-Rooter experienced a significant margin contraction and a decline in residential revenue.

Chemed Corporation delivered a mixed performance in the third quarter of 2025. The company achieved a 3.1% increase in consolidated revenue, reaching $624.9 million. However, GAAP Diluted EPS decreased by 10.8% to $4.46, and Adjusted Diluted EPS decreased by 6.6% to $5.27. The VITAS segment saw a 4.2% increase in net patient revenue and growth in Average Daily Census and admissions, while the Roto-Rooter segment experienced a 1.1% revenue increase.

Chemed delivered slight revenue growth in Q2 2025, but net income and EPS declined due to higher costs and Medicare Cap charges at VITAS.

Chemed delivered solid Q1 2025 results, with revenue rising to $646.9M and adjusted EPS reaching $5.63. Growth was driven by VITAS Healthcare, bolstered by the recent Covenant Health acquisition, while Roto-Rooter remained relatively flat.

Chemed Corporation reported Q4 2024 revenue of $640.0 million, an increase of 9.2% year-over-year. Net income attributable to common stock was $90.3 million, with EPS of $6.02 and adjusted EPS of $6.83. VITAS segment revenue grew 17.4%, while Roto-Rooter saw a slight revenue decline. Free cash flow remained strong, and the company repurchased shares worth $212.8 million.

Chemed Corporation reported a 7.4% increase in revenue to $606.2 million for Q3 2024. GAAP diluted EPS increased by 1.4% to $5.00, and adjusted diluted EPS rose by 6.0% to $5.64. The VITAS segment saw a 17.3% increase in net patient revenue, while Roto-Rooter's revenue decreased by 6.9%.

Chemed Corporation reported a 7.6% increase in revenue to $595.9 million and a 34.1% increase in adjusted diluted EPS to $5.47 for the second quarter of 2024. The VITAS segment saw a significant revenue increase of 16.7%, while Roto-Rooter experienced a 5.0% revenue decrease.

Chemed Corporation reported a 5.2% increase in revenue to $589.2 million and a GAAP diluted EPS of $4.24, up 18.4%. Adjusted diluted EPS increased by 21.5% to $5.20. VITAS Healthcare saw a 14.0% increase in net patient revenue, while Roto-Rooter experienced a 5.8% decrease in revenue.

Chemed Corporation reported a 7.2% increase in revenue to $585.9 million and a 42.9% increase in GAAP EPS to $5.90 for the fourth quarter of 2023. Adjusted EPS increased by 35.0% to $6.60. VITAS Healthcare saw a 13.6% increase in net patient revenue, while Roto-Rooter's revenue decreased slightly by 1.1%.

Chemed Corporation reported a 1.0% increase in revenue to $547 million for Q4 2022. GAAP diluted EPS was $4.13, and adjusted diluted EPS increased by 2.7% to $5.39. The VITAS segment experienced a revenue decline, while Roto-Rooter showed revenue growth.

Chemed Corporation reported third-quarter 2022 results, with revenue declining by 2.3% to $526 million. GAAP diluted EPS was $3.78, and adjusted diluted EPS decreased by 6.3% to $4.74. The company increased its 2022 earnings guidance.

Chemed Corporation reported a slight decline in revenue but an increase in GAAP diluted earnings per share. The VITAS segment experienced revenue and ADC declines, while Roto-Rooter saw revenue growth.

Chemed Corporation reported a slight increase in revenue for Q1 2022, with overall revenue rising by 0.6% to $531 million. While Roto-Rooter saw a revenue increase, VITAS experienced a decline. GAAP EPS increased by 5.2% to $4.22, and adjusted EPS increased by 7.9% to $4.79.

Chemed Corporation reported a 1.4% increase in revenue to $541 million. GAAP EPS was $4.81 and adjusted EPS increased by 2.3% to $5.25. The VITAS segment experienced revenue and ADC declines while Roto-Rooter saw revenue and net income growth.

Chemed Corporation reported a 2.0% increase in revenue to $539 million. GAAP diluted EPS increased by 9.9% to $4.55, and adjusted diluted EPS increased by 4.1% to $5.06. The VITAS segment experienced a revenue decline, while Roto-Rooter demonstrated strong revenue growth.

Chemed Corporation reported a 6.0% increase in revenue to $532 million for Q2 2021. GAAP EPS decreased by 29.9% to $3.51, while adjusted EPS increased by 4.3% to $4.60. The VITAS segment experienced declines in net patient revenue and ADC, while the Roto-Rooter segment saw significant revenue growth.

Chemed Corporation reported a 2.2% increase in revenue to $527 million for Q1 2021. GAAP Diluted EPS increased by 18.6% to $4.01, and Adjusted Diluted EPS rose by 20.7% to $4.44. The VITAS segment experienced a revenue decline, while Roto-Rooter saw significant revenue growth.

Chemed Corporation reported a 2.1% increase in revenue to $533 million. GAAP diluted EPS increased by 75.8% to $6.96, and adjusted diluted EPS increased by 21.6% to $5.13. VITAS segment revenue declined by 2.3%, while Roto-Rooter's revenue increased by 10.2%.

Chemed Corporation reported a 9.9% increase in revenue, reaching $528 million. GAAP diluted EPS increased by 16.3% to $4.14, and adjusted diluted EPS increased by 40.5% to $4.86. The VITAS segment saw a 4.8% increase in net patient revenue, while Roto-Rooter experienced a 20.4% increase in revenue.

Chemed Corporation reported a 6.0% increase in revenue to $502 million. GAAP diluted EPS increased by 62.7% to $5.01, and adjusted diluted EPS increased by 31.3% to $4.41.

Chemed Corporation reported an 11.6% increase in revenue to $516 million for the first quarter of 2020. GAAP diluted EPS increased by 25.2% to $3.38, and adjusted diluted EPS increased by 26.0% to $3.68.

Chemed Corporation reported a 14.2% increase in revenue to $522 million for Q4 2019. GAAP diluted EPS increased by 21.5% to $3.96, and adjusted diluted EPS increased by 26.0% to $4.22.